Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT027 in Advanced Peritoneal Malignancies
NCT06912152Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- May 2025
- Primary completion
- Oct 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT027 CAR-T cells in peritoneal neoplasms and solid tumor, sponsored by Zhejiang University. Primary endpoint: Incidence of Adverse events after MT027 cells infusion at 28 days. Started May 2025; status: recruiting.
02
Drugs
MT027 CAR-T cells
03
Conditions
peritoneal neoplasmssolid tumor
Beyond the preview
Go deeper on NCT06912152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912152.